Table 2.
Use of Concomitant Medications and Drug Insurance Reported by 50 Survey Respondents with Hepatitis C Virus, Seen by Hepatology Services, Capital District Health Authority, Halifax, Nova Scotia, Canada, 2008
| Characteristic | No. (%) of Respondents* |
|---|---|
| Drug utilization | |
| Prescription medications*† | |
| Antidepressants (N06A) | 19 (38) |
| Antihypertensives (C09A) | 12 (24) |
| Anxiolytics (N05B) | 10 (20) |
| Nonsteroidal anti-inflammatory drugs (M01A) | 10 (20) |
| H2-receptor antagonists (A02B) | 6 (12) |
| Proton pump inhibitors (A02B) | 6 (12) |
| Dermatologic agents (D07A) | 5 (10) |
| Diuretic agents (C03C) | 5 (10) |
| Nonprescription medications and complementary remedies* | |
| Vitamins | 23 (46) |
| Pain reliever | 18 (36) |
| Skin care product | 7 (14) |
| Milk thistle | 7 (14) |
| Calcium | 6 (12) |
| Drug insurance | |
| Current drug coverage | |
| I have a private drug insurance plan | 33 (66) |
| I am a client of Nova Scotia Community Services and have coverage through Pharmacare | 13 (26) |
| Drug benefit plan claims procedure | |
| Have to pay a fee to the physician to fill out forms for the drug benefit plan | 8 (16) |
| Have to collect forms and mail, email, fax, or deliver them to the drug benefit plan | 8 (16) |
| Have to pay for the drug first and then seek reimbursement with receipts | 30 (60) |
*
Data are reported here for medications and products identified by at least 5 patients.
†
Codes from the World Health Organization Anatomical Therapeutic Chemical System are provided in parentheses.